Ann: DEP irinotecan outperforms in pancreatic cancer model, page-31

I'm not arguing at all that this finding isn't extremely significant, just that I think the share price won't take off until phase II clinical results are released.

It's another result showing amazing efficacy of a very toxic anticancer drug in a mouse model of pancreatic cancer, which has few current treatment options. And all previous results suggest that the DEP-irinotecan should be much less toxic than irinotecan alone. So another very exciting candidate in the pipeline of DEP-anticancer drugs.

But just judging by previous announcements, it hasn't been enough to convince the market of how incredibly valuable this technology is. But once the first phase II results showing efficacy are announced, there won't be any question at all.